| First Author | Houde N | Year | 2022 |
| Journal | Cell Rep | Volume | 38 |
| Issue | 2 | Pages | 110223 |
| PubMed ID | 35021072 | Mgi Jnum | J:320530 |
| Mgi Id | MGI:6874529 | Doi | 10.1016/j.celrep.2021.110223 |
| Citation | Houde N, et al. (2022) Fine-tuning of MEK signaling is pivotal for limiting B and T cell activation. Cell Rep 38(2):110223 |
| abstractText | MEK1 and MEK2, the only known activators of ERK, are attractive therapeutic candidates for both cancer and autoimmune diseases. However, how MEK signaling finely regulates immune cell activation is only partially understood. To address this question, we specifically delete Mek1 in hematopoietic cells in the Mek2 null background. Characterization of an allelic series of Mek mutants reveals the presence of distinct degrees of spontaneous B cell activation, which are inversely proportional to the levels of MEK proteins and ERK activation. While Mek1 and Mek2 null mutants have a normal lifespan, 1Mek1 and 1Mek2 mutants retaining only one functional Mek1 or Mek2 allele in hematopoietic cell lineages die from glomerulonephritis and lymphoproliferative disorders, respectively. This establishes that the fine-tuning of the ERK/MAPK pathway is critical to regulate B and T cell activation and function and that each MEK isoform plays distinct roles during lymphocyte activation and disease development. |
